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glucosyl- or galactosylceramide. Sequential addition of 
galactose, N-acetylgalactosamine, and neuraminic acid 
groups to glucosylceramide gives rise to a diverse array of 
glycolipids termed globosides and gangliosides, which pat-
tern the cell surface and are critically important mediators 
of higher order mammalian physiology ( 2 ). 
 In de novo sphingolipid synthesis, dihydroceramide is 
formed by transfer of a fatty acid chain from fatty acid-CoA 
to the amino group of sphinganine. This reaction is cata-
lyzed by a family of six ceramide synthases (CerS1-6; also 
referred to as LASS1-6), in the endoplasmic reticulum. 
Dihydroceramide is then enzymatically desaturated to 
form ceramide. Sphingosine may also be N-acylated by 
CerS enzymes, directly forming ceramide through what is 
known as the sphingolipid salvage pathway. The fatty acids 
transferred to sphinganine or sphingosine vary in length 
from 14 to 28 carbons, are most commonly saturated or 
mono-unsaturated, and may be hydroxylated ( 1, 3 ). Each 
CerS enzyme exhibits a preference for fatty acids of different 
length, for example CerS1 preferentially catalyses the ad-
dition of 18-carbon (C18) fatty acids to sphinganine ( 4 ), 
whereas CerS2 preferentially adds long chain (C22–C26) 
fatty acids ( 5 ). The different acyl chain lengths of the cer-
amides appear to confer distinct functional roles; for 
example, long chain ceramides synthesized by CerS2 
are essential constituents in myelin ( 6 ), C18 ceramide is 
an important pro-apoptotic mediator ( 7, 8 ), and very long 
chain ceramides synthesized by CerS3 are critically important 
for skin barrier function ( 9 ). 
 There are two methods that are regularly used for assay-
ing ceramide synthase activity. One method uses tritiated 
sphinganine or sphingosine and resolution of ceramide 
products using TLC ( 10, 11 ). Tritiated chemicals, although 
safe if used properly, are dangerous if ingested. Unlike 
other common radiochemicals, tritium is diffi cult to moni-
tor. In most countries, work with radiochemicals involves 
extra paperwork whereas work with fl uorescent substrates 
is safer and involves much less bureaucracy. An alternative 
radioactive assay with  14 C-labeled fatty acid substrate has 
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 The sphingolipids are a diverse family of lipids and gly-
colipids that are essential for compartmentalization of cell 
membranes as signaling metabolites and as membrane an-
chors for carbohydrate patterning of the extracellular sur-
face ( 1, 2 ). The lipid ceramide is the central metabolite of 
the sphingolipid family and can be modifi ed on its primary 
hydroxyl headgroup through the addition of a phospho-
choline group forming sphingomyelin, a phosphate group 
forming ceramide 1-phosphate, or a hexose group forming 
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at 1,000  g for 10 min to clear unbroken cells and nuclei. The 
supernatant (crude cell homogenate) was dispensed into aliquots 
and stored at   80°C. The protein concentration was determined 
by bicinchoninic acid (BCA) assay relative to BSA standards. To 
obtain crude tissue homogenates, 50–100 mg fresh mouse tissues 
were homogenized in 2 ml lysis buffer as detailed above. 
 Fluorescent CerS assay 
 The assay was performed essentially as described ( 10 ) except 
using NBD-sphinganine in place of unlabeled sphinganine spiked 
with tritiated sphinganine. Reaction buffer was 20 mM Hepes, 
pH 7.4, 25 mM KCl, 2 mM MgCl 2 , 0.5 mM DTT, 0.1% (w/v) fatty 
acid-free BSA, 10   M NBD-sphinganine, and 50   M fatty acid-
CoA. For many assays, sucrose (250 mM) was included in the re-
action buffer to maintain consistency in reaction conditions 
across different samples (i.e., due to different volumes of homo-
genate in different reactions). Our results indicated that the in-
clusion of sucrose did not adversely affect the reaction rate. The 
100   l reactions were started with the addition of 50   g homoge-
nate protein and incubated with shaking at 35°C for 30–120 min. 
Reactions were stopped with the addition of 250   l chloroform/
methanol (2:1). The tubes were vortexed thoroughly, centri-
fuged at 21,000  g for 1 min to separate the phases, and the lower 
organic phase was transferred to a 5 ml glass tube. The aqueous 
phase was reextracted as above and the two organic extracts were 
combined then dried down in a SpeedVac SC210 (Thermo-
Fisher Scientifi c), resuspended in 100   l methanol with vortexing, 
spotted (2 × 2   l) onto aluminum-backed Silica Gel 60 TLC 
plates, and resolved in chloroform/methanol/water (8:1:0.1, 
v/v/v) ( 16 ). Fluorescence was detected directly on the TLC 
plates using a LAS Mini 4000 imaging system and fl uorescent pixel 
intensity was quantifi ed using the associated ImageQuant ven-
dor software (GE Healthcare, Rydalmere, NSW, Australia). NBD-
sphinganine standards of different concentrations were spotted 
onto the TLC plate before imaging, in order to construct a stan-
dard curve for fl uorescence vs pmoles compound. 
 To assess the effect of FTY720, AAL(S), and Fumonisin B 1 on 
enzyme kinetics, the cell homogenate was preincubated for 5 min 
with each inhibitor, then added to an equal volume of reaction 
buffer containing the substrates to start the reactions, such that 
the fi nal inhibitor concentration was 20   M. 
 NBD-dihydroceramide purifi cation and verifi cation by 
high-resolution MS 
 Reactions (100   l) containing 20   M NBD-sphinganine, 100   M 
C16:0- or C24:1-CoA, and 50   g CerS5- or CerS2-expressing cell 
extract were incubated for 4 h at 35°C. The total reaction product 
was extracted and resolved on TLC as described above. Fluores-
cent products, which were clearly visible under laboratory lights 
due to their abundance, were cut out of the TLC and washed off 
the silica with 200   l chloroform/methanol (2:1), into glass test 
tubes. The extracts were dried down and reconstituted in 0.5 ml 
methanol, then analyzed on an Orbitrap LTQ XL mass spectrom-
eter (Thermo Fisher Scientifi c, North Ryde, NSW, Australia) 
using a nanospray (nano-electrospray) ionization source. The in-
strument was calibrated with a standard calibration solution (as 
outlined in the instrument manual) on the day of analysis. The 
instrument conditions were optimized for sensitivity on each 
compound of interest using LC tune software. The analysis was 
carried out in positive ion mode using the orbitrap FTMS ana-
lyzer at a resolution of 100,000 fwhm (full width at half maximum). 
Samples (5   l) were drawn up into a glass needle and inserted 
into the nanospray source. Ions generated were measured over 
the mass range 150–2000 Da. Data was acquired in full scan mode 
over 60 s and analyzed using the Qual Browser feature in Xcali-
ber 2.1 (Thermo Fisher Scientifi c). 
also been described ( 12 ). Another approach is to quantify 
ceramide formation using LC-MS/MS ( 13 ). Although 
highly accurate and sensitive, this approach requires 
lengthy access to highly specialized equipment and spe-
cifi c expertise. The HPLC takes 15 min per sample. For 
a relatively small experiment involving, for example, eight 
samples in triplicate and external standards at the start 
and end of the run, plus regular blanks, the machine time 
required is at least a full working day and usually an over-
night booking. This method is therefore somewhat im-
practical when equipment is shared or centralized and 
regular CerS assays are needed. It is also associated with 
considerable costs when access or cost-recovery fees are 
charged, as is commonly the case with expensive core 
equipment. 
 Herein, we describe a simple fl uorescent assay for CerS 
activity in cultured cell or tissue homogenates, which uses 
commercially available sphinganine labeled with an NBD 
fl uorescent group (NBD-sphinganine; (2S,3R)-2-amino-18-
((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)octadecane-
1,3-diol). We show that this substrate is effi ciently utilized 
by CerS enzymes, and that the assay can be used to screen 
for inhibitors of CerS activity. 
 MATERIALS AND METHODS 
 Materials 
 NBD-sphinganine, nervonoyl (C24:1)-CoA, sphinganine, C16:0 
dihydroceramide, and C24:1 dihydroceramide were purchased 
from Avanti Polar Lipids (Alabaster, AL ). Palmitoyl (C16:0) 
and stearoyl (C18:0)-CoA, and Fumonisin B 1 were from Sigma 
Aldrich (Castle Hill, NSW, Australia). Silica Gel 60 TLC plates were 
from Merck (Kilsyth, VIC, Australia). All cell culture media re-
agents were from Invitrogen (Mulgrave, VIC, Australia). Human 
CerS2 and CerS5 cDNAs were purchased as full-length True-
Clone cDNAs from OriGene (Rockville, MD) in vector pCMV-
XL6 FTY720 was purchased from Cayman Chemical (Ann 
Arbor, MI). AAL(S) was synthesized following the procedure re-
ported by Hinterding et al. ( 14 ). The synthesis of AAL(S) analogs 
HDTF020, HDTG022, and HDTG046 will be described in detail 
in a separate publication. 
 Cell culture and transfection 
 HEK293 cells were grown in DMEM medium supplemented with 
10% FBS, 2 mM L-glutamine, and penicillin/streptomycin. Cells 
were transfected in DMEM containing 2% FBS with polyethylenimine 
(PEI) reagent (Sigma Aldrich) ( 15 ). Each 175 cm 2 fl ask of cells was 
transfected with 50   g plasmid cDNA and 75   l of a 1 mg/ml 
stock of PEI. DNA and PEI were premixed for 10 min before adding 
to the cells, and cells were harvested 24 h after transfection. 
 Preparation of cell or tissue homogenates 
 Preparation of cell or tissue homogenates was performed 
essentially as described by Lahiri et al ( 10 ). Two 175 cm 2 fl asks of 
cells were scraped into 20 ml PBS using a cell scraper, then pel-
leted and resuspended in 1 ml lysis buffer containing 20 mM 
Hepes, pH 7.4, 25 mM KCl, 2 mM MgCl 2 , 250 mM Sucrose, and 
complete protease inhibitor cocktail (Roche). The cells were 
broken on ice with 50 to 100 strokes of a small glass Dounce 
homogenizer (checking cells under a light microscope to ensure 
that they were broken). The suspension was then centrifuged 
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level availability of substrate becomes rate-limiting for prod-
uct formation, as illustrated for the CerS2-driven reaction 
in  Fig. 1C . 
 The identity of the products formed was confi rmed us-
ing a high-resolution Orbitrap mass spectrometer: C16:0 
and C24:1 NBD-dihydroceramide were prepared using the 
respective fatty acid-CoA substrates and lysates of HEK293 
cells overexpressing CerS5 (C16:0) or CerS2 (C24:1), and 
purifi ed from TLC plates as described in Materials and 
Methods. Precise  m/z values of 740.5277 (M + Na; expected 
 m/z 740.5302; mass accuracy 3.38 ppm) and 850.6369 
(M + Na; expected  m/z 850.6398; mass accuracy 3.47 ppm) 
were obtained for C16:0 and C24:1 NBD-dihydroceramide, 
respectively, indicating that the expected products had 
been formed. As indicated in  Fig. 2 , (right-most lane) 
C16:0 NBD-dihydroceramide migrates more slowly on 
TLC than C24:1 NBD-dihydroceramide, using the chol-
oroform/methanol/water solvent (8:1:0.1) system ( 16 ). 
 It was also possible to detect CerS activity toward C16:0, 
C18:0, and C24:1-CoA substrates in tissue homogenates 
( Fig. 2 ). Using equivalent amounts of protein, the liver 
homogenate contained much more C24:1 CerS activity, 
and slightly higher C16:0 CerS activity, whereas C18:0 CerS 
activity was similar, if not slightly higher in cerebellum. 
This pattern is in agreement with the published observa-
tion that CerS2 mRNA is expressed at a much higher level 
in the liver ( 5, 11 ). However, CerS1 expression is highest 
 CerS assay using LC-MS/MS 
 To measure ceramide formation using LC-MS/MS, the assay 
was performed essentially as described above except that sphin-
ganine was used as the substrate in place of NBD-sphinganine. 
Note that for these experiments measuring  K m , the sphinganine 
concentration varied from 0.625 to 40   M, while all other condi-
tions were kept constant. Each sample was spiked with 40   l of 
0.5   M C17:0 ceramide as an internal standard for recovery and 
mass spectrometry immediately prior to stopping the reactions 
with chloroform/methanol. Reactions were then extracted and 
dried as described above and resuspended in 200   l HPLC 
mobile phase consisting of 20%:80% Mobile phase A (2 mM am-
monium formate/0.2% formic acid in water): Mobile phase B 
(1 mM ammonium formate/0.2% formic acid in methanol). Lip-
ids were resolved on a 3 × 150 mm Agilent XDB-C8 column 
(5   M pore size) at a fl ow rate of 0.5 ml/min using a 15 min gra-
dient starting at 20:80 A:B, increasing to 100% B after 1 min, 
holding at 100% B for 13 min, then reequilibrating to 20:80 A:B 
for 1 min. Lipids were detected on a Thermo Quantum Access 
triple quadrupole mass spectrometer operating in positive ion 
mode. Precursor and product ions used to identify reaction prod-
ucts were as follows: C17:0 ceramide,  m/z 552.6  → 264.1; C16:0 
dihydroceramide,  m/z 540.5  → 266.1; C24:1 dihydroceramide, 
 m/z 650.7  → 266.1. Linear calibration curves were constructed 
using synthetic C16:0 and C24:1 dihydroceramide external stan-
dards over the range 0.032–100 pmol on-column. The ratio of 
external to internal standard peak area was used to construct cali-
bration curves and determine the amount of dihydroceramide 
product in experimental samples ( 13 ). 
 Statistical analysis and curve fi tting 
 All curves were fi t using GraphPad PRISM software, which di-
rectly calculates  K m and  V max from the Michaelis-Menten curves. 
Coeffi cient of Variation (%CV) was calculated as the standard 
deviation divided by the mean, expressed as a percentage. 
 RESULTS 
 Suitability of NBD-sphinganine as a substrate for 
CerS assays 
 We fi rst determined whether NBD-sphinganine would 
be tolerated as a substrate for CerS enzymes. Homoge-
nates were prepared from untransfected HEK293 cells or 
cells expressing human CerS2 or CerS5, and CerS activity 
was determined using C16:0- or C24:1-CoA as the fatty acid 
substrate. No product was formed in the absence of cell 
lysate ( Fig. 1A , lanes 3 and 7) or NBD-sphinganine (lane 1) 
and only a faint smear was visible in the absence of added 
fatty acid-CoA substrate (lane 2). The amount of product 
formed was dependent on the particular CerS enzyme 
expressed ( Fig. 1A, B ), and linear with respect to lysate 
protein concentration ( Fig. 1B ). Our results are in agree-
ment with previous studies showing that CerS5 preferen-
tially utilizes shorter-chain fatty acid substrates (C14–C18), 
whereas CerS2 preferentially utilizes long-chain substrates 
(C22–C26) ( 11 ); and results indicating that overexpress-
ing CerS5 in HEK293 cells produces a much higher 
specific activity than CerS2 ( 10 ). Product formation 
was linear with respect to time under conditions in which 
no more than 30% of the NBD-sphinganine substrate (i.e., 
300 pmoles) was converted to product ( Fig. 1C ); above this 
 Fig.  1. Synthesis of C16:0 or C24:1 NBD-dihydroceramide cata-
lyzed by endogenous or overexpressed ceramide synthases. A: TLC 
image illustrating that CerS reaction proceeds only in the presence 
of cell lysate and fatty acid-CoA. Homogenates of untransfected 
(lanes 1, 2, 4, and 8), CerS2- (lanes 5 and 9), or CerS5-expressing 
(lanes 6 and 10) HEK293 cells (25   g/reaction) were incubated 
for 30 min with 10   M NBD-sphinganine and 50   M C16:0-CoA 
(lanes 3–6) or C24:1-CoA (lanes 7–10). Lane 1: no NBD-sphinga-
nine control; Lane 2: No fatty acid-CoA control; Lanes 3 and 7: no 
homogenate control (i.e., no enzyme). B: Product formed as a 
function of lysate concentration, using (i) C16:0-CoA or (ii) C24:1-
CoA as the fatty acid substrate. Reactions in B(i) were run for 30 min 
while those in (ii) were run for 60 min. C: Product formation as a 
function of time, using CerS5-expressing cell homogenate (5   g/
reaction) and C16:0-CoA (50   M), or CerS2-expressing homogenate 
(50   g/reaction) and C24:1-CoA (50   M). Data points are mean 
and standard error of triplicate assays and representative of two or 
more independent experiments. 
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triplicate reactions in the range 2%–10% in multiple differ-
ent experiments. When the amount of NBD-ceramide on 
the TLC plate dropped below 0.25 pmoles, the %CV in-
creased appreciably (>20%). Note that this limit of detec-
tion was determined by running reactions and resolving the 
product on TLC (as distinct from determining the limit of 
detection using a synthetic standard), and is therefore a re-
fl ection of the limit of resolution for the assay with cell lysate. 
 Comparison of NBD-sphinganine to unlabeled 
sphinganine 
 To determine how NBD-sphinganine compares to the 
natural substrate in terms of enzyme affi nity, the  K m for 
NBD-sphinganine, with product detected using TLC and a 
fl uorescence imager, was compared with that obtained 
with unlabeled sphinganine, in which the product was de-
tected using LC-MS/MS. In three independent experi-
ments with C16:0-CoA as the fatty acid substrate, a  K m 
of 1.91 ± 0.84   M (mean ± SE) was measured for NBD-
sphinganine. This is very similar to the average  K m of 1.16 ± 
0.36   M measured for sphinganine using the LC-MS assay. 
As C24:1 CoA is utilized by different CerS enzymes com-
pared with C16:0 CoA, we also measured the affi nity of 
CerS enzymes for NBD-sphinganine using C24:1 CoA as 
the fatty acid substrate: an average  K m of 3.61 ± 1.86   M 
was obtained with NBD-sphinganine, and 3.05 ± 0.81   M 
with sphinganine. A representative experiment for each 
condition is shown in  Fig. 3 . These results indicate that 
NBD-sphinganine is a good substrate for ceramide syn-
thases, with very similar affi nity to the natural substrate. 
in the brain, and we might therefore have expected signifi -
cantly higher C18:0 CerS activity in cerebellum. This was 
not observed, possibly indicative of the balance between 
CerS1 and other enzymes that possess C18 CerS activity, 
specifi cally CerS4 and CerS5; or posttranscriptional regu-
lation of CerS1. It is also possible that abundant lipids in 
the crude brain homogenate interfere somewhat with the 
CerS assay. 
 Limit of detection 
 Using our assay, it is possible to detect 0.5 pmoles of reac-
tion product on the TLC plate, yielding %CV values for 
 Fig.  2. Synthesis of C16:0, C18:0 and C24:1 NBD-dihydroceramide 
catalyzed by endogenous tissue ceramide synthases. CerS reactions 
(120 min) were run in the presence of 10   M NBD-sphinganine, 
50   M fatty acid-CoA (as indicated on the fi gure), and 50   g mouse 
liver or cerebellum homogenate. The fi rst two lanes on the left were 
from reactions with tissue homogenate but no fatty acid-CoA. The 
right-most lane (Std) contains a mixture of C16:0 and C24:1 NBD-
dihydroceramide standards prepared as described in text. 
 Fig.  3. NBD-sphinganine is equivalent to natural 
sphinganine as a substrate for endogenous ceramide 
synthases. Untransfected HEK293 cell extracts were 
incubated with 100   M C16:0-CoA (A and B) or 
C24:1-CoA (C and D) and varying concentrations of 
NBD-sphinganine (A and C) or sphinganine (B and D). 
Product formed was quantifi ed by TLC with a fl uores-
cent imager (A and C) or LC-MS/MS (B and D). Data 
points are the mean and standard error of triplicate 
reactions, and  K m values derived results from three 
such assays are given in-text. 
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change in the  K m but a reduction in the  V max from 34.8 
product/min/mg protein in the vehicle control to 12.0 
and 9.99 pmoles product/min/mg protein, respectively, 
for FTY720 and AAL(S). We further investigated whether 
two key structural features of FTY720/AAL(S) are re-
quired for CerS inhibition: the acyl lipid tail and the 
amine group ( Fig. 4B ). Both the amine group (eliminated 
in HDTF020) and the lipid tail (eliminated in HDTG046) 
were essential for inhibition of C16:0 dihydroceramide 
synthesis, and reducing the lipid tail by only three carbons 
(HDTG022) reduced the extent of inhibition at 10   M 
from 50% to only 16% inhibition, relative to the vehicle 
control ( Fig. 4A ). 
 C16:0 CerS activity in our assay was also inhibited by 
Fumonisin B 1 (FB 1 ), a well established CerS inhibitor 
( Figs. 4C, D ) ( 20 ). Inhibition was competitive with respect 
to NBD-sphinganine ( K m increased from 1.76 to 46.8   M), 
but unlike FTY720 and AAL(S), inhibition with FB 1 showed 
the pattern of uncompetitive inhibition with respect to 
C16-CoA (both  V max and  K m decreased). 
 Inhibition of CerS activity by FTY720: structural 
requirements for inhibition 
 Two publications from 2009 demonstrated inhibition of 
CerS activity by the new therapeutic FTY720, recently ap-
proved for treatment of relapsing multiple sclerosis. 
FTY720 was reported to inhibit endogenous C16, C18, and 
C24 CerS activity of several human cell lines ( 17 ) as well as 
primary human aortic endothelial cells ( 13 ). We fi rst 
tested whether the nonphosphorylatable, chiral deoxy 
FTY720 analog AAL(S) ( 18, 19 ) inhibited C16:0 CerS 
activity in cell homogenates. C16:0 CerS activity was inhib-
ited with slightly greater potency by AAL(S) when 
compared with FTY720 ( Fig. 4A ). The mode of inhibition 
for both FTY720 and AAL(S) was clearly competitive with 
respect to NBD-sphinganine ( Fig. 4C ), as the  K m for NBD-
sphinganine increased from 1.76   M in the vehicle control 
to 28.6   M (FTY720) or 55.0   M [AAL(S)], whereas the 
 V max did not decrease. In accordance with competition for 
the sphinganine binding site, inhibition was noncompetitive 
with respect to C16:0-CoA ( Fig. 4D ), with no signifi cant 
 Fig.  4. Inhibition of endogenous C16 dihydroceramide synthesis by FTY720. A: Effect of FTY720 analogs 
at a concentration of 10   M on C16:0 CerS activity of untransfected HEK293 lysates. Lysate in reaction buffer 
was preincubated for 5 min with compounds before addition of 50   M C16:0-CoA and 10   M NBD-sphinga-
nine to start the reactions. Product formed was normalized to vehicle control. B: Structures of FTY720 ana-
logs tested. C: Effect of FTY720 (  ), AAL(S) (  ), FB 1 (×), or DMSO vehicle control (  ) on endogenous 
CerS activity of HEK293 homgenates, in the presence of 50   M C16:0-CoA and varying concentrations of 
NBD-sphinganine. D: Effect of inhibitors on C16:0 CerS activity in the presence of 10   M NBD-sphinganine 
and varying concentrations of C16:0-CoA. 
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Picomole quantities of reaction product were detected on 
the TLC plates with very low experimental replicate variabil-
ity (CV < 10%). One picomole corresponds to only 0.1% of 
the standard 1 nmole substrate added to each reaction, pro-
viding a large dynamic range for detecting variation in activ-
ity among different biological samples. 
 The fl uorescent NBD-sphinganine substrate is commer-
cially available and costs approximately the same as the 
tritiated substrate per assay, assuming that 1 nmole NBD-
sphinganine in a 100   l reaction is used for the fl uores-
cent version and 0.2–0.25   Ci tritiated sphinganine per 
reaction is used for the radioactive assay, as published 
( 10, 11 ). Although per-assay costs are similar, it is much 
cheaper to implement the fluorescent assay because 
smaller amounts of labeled substrate can be purchased 
compared with the minimum amount of tritiated substrate 
that can be purchased. Costs can be further reduced by 
running 50   l reactions, making the fl uorescent assay 
more cost effective. The LC-MS/MS based assay is very sen-
sitive, with a sub-pM limit of detection, but will generally 
cost much more when equipment access or cost recovery 
fees must be paid. An important advantage with the fl uo-
rescent assay format is that the fl uorescent signal on the 
TLC plate can be quantifi ed immediately using densitom-
etry. To detect tritiated ceramide, one must either scrape 
the ceramide bands from the TLC into vials and quantify 
the radioactivity by scintillation counting or expose the 
TLC plate to fi lm or a phosphorimager screen. Due to its 
lower energy emission in comparison to other radioiso-
topes, it can take several days for suffi cient signal to de-
velop. The radioactive assay format also requires that 
radioactive material be used in a fume hood (due to the 
use of chloroform), which can create logistical diffi culties 
in countries where the use of radioactive substances is 
tightly regulated. A disadvantage with the fl uorescent 
format is that the signal can fade under laboratory lights if 
adequate precautions are not taken to protect the samples 
from light. TLC-based methods are able to distinguish 
long chain (C14–C18) from very long chain (C22–C26) 
ceramide and dihydroceramide but cannot clearly distin-
guish C16:0 from C18:0 or C24:0 from C24:1 dihydrocer-
amde, for example ( 16, 23 ). Although this is a drawback 
with any TLC-based approach, the appearance of a prod-
uct band in our assay is dependent on provision of a par-
ticular fatty acid-CoA substrate ( Figs. 1A and 2 ). Individual 
dihydroceramide species can be readily distinguished us-
ing LC-MS/MS, which is an advantage of this approach. 
 In summary, we present a fl uorescent alternative to tri-
tium or LC-MS/MS for quantifying ceramide synthase 
activity. It is anticipated that this fl uorescent assay format 
will increase the accessibility of CerS assays throughout the 
scientifi c community.  
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